| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Qianjiang Yongan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.20 |
| 52 Week High | CN¥11.21 |
| 52 Week Low | CN¥5.45 |
| Beta | 0.24 |
| 1 Month Change | -0.14% |
| 3 Month Change | -18.18% |
| 1 Year Change | -28.43% |
| 3 Year Change | -21.14% |
| 5 Year Change | -38.20% |
| Change since IPO | -50.40% |
Recent News & Updates
Shareholder Returns
| 2365 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 7.0% | 4.9% | 2.1% |
| 1Y | -28.4% | -13.4% | -14.2% |
Return vs Industry: 002365 underperformed the CN Pharmaceuticals industry which returned -14.4% over the past year.
Return vs Market: 002365 underperformed the CN Market which returned -14.6% over the past year.
Price Volatility
| 2365 volatility | |
|---|---|
| 2365 Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002365's share price has been volatile over the past 3 months.
Volatility Over Time: 002365's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,004 | n/a | www.chinataurine.com |
Qianjiang Yongan Pharmaceutical Co., Ltd. manufactures and sells taurine in China. It produces ethylene oxide, water reducers, and health products. The company engages in scientific research and technical service, wholesale and retail trade, leasing and business services, and crop farming.
Qianjiang Yongan Pharmaceutical Co., Ltd. Fundamentals Summary
| 2365 fundamental statistics | |
|---|---|
| Market cap | CN¥2.12b |
| Earnings (TTM) | -CN¥12.31m |
| Revenue (TTM) | CN¥972.89m |
2.2x
P/S Ratio-172.3x
P/E RatioIs 2365 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2365 income statement (TTM) | |
|---|---|
| Revenue | CN¥972.89m |
| Cost of Revenue | CN¥721.21m |
| Gross Profit | CN¥251.68m |
| Other Expenses | CN¥263.99m |
| Earnings | -CN¥12.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 25.87% |
| Net Profit Margin | -1.27% |
| Debt/Equity Ratio | 0.5% |
How did 2365 perform over the long term?
See historical performance and comparison